STOCK TITAN

Ipsen - IPSEY STOCK NEWS

Welcome to our dedicated news page for Ipsen (Ticker: IPSEY), a resource for investors and traders seeking the latest updates and insights on Ipsen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ipsen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ipsen's position in the market.

Rhea-AI Summary
Ipsen and Skyhawk Therapeutics have announced a collaboration to develop small molecules targeting RNA for rare neurological diseases. Ipsen will have exclusive global rights to two candidates and will lead further development leveraging its expertise in movement disorders. The partnership aims to explore previously undruggable RNA targets using Skyhawk's platform technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.27%
Tags
none
-
Rhea-AI Summary
Marengo Therapeutics and Ipsen collaborate to develop a novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment. Marengo receives milestone payments and royalties, with Ipsen nominating the first clinical drug candidate from the partnership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.54%
Tags
none
-
Rhea-AI Summary
Ipsen (IPN) and Medison Pharma announce the Health Canada approval for Bylvay™ (odevixibat) for the treatment of pruritus in patients aged 6 months or older with Progressive Familial Intrahepatic Cholestasis (PFIC). Bylvay is the first oral treatment available in Canada for this rare genetic condition, offering new hope for patients and their families.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Ipsen

OTC:IPSEY

IPSEY Rankings

IPSEY Stock Data

9.72B
30.55M
0.01%
Medicinal and Botanical Manufacturing
Manufacturing
Link
France
Boulogne Billancourt